Why Zilosul could be a golden goose!!, page-39

Mozz I don't think 30% royalty is NO longer realistic for PAR particularly for global license deal. Hopefully they'll surprise on the upside of 15% or above.

It's also critical to note Humira historic price tag versus Zilosul (US$70k to $2.5k) when consideration is given to 10:1 RA to OA patient TAM.

DMOAD pricing is possible but FDA will still likely want post marketing longitudinal studies IMO. As you know they have been increasingly engaged with KOL to help develop a surrogate end point (use of predictive biomarkers versus MRI joint spacing) BUT this also means we're still quite early in this area of ground breaking development. Definitely past the stage of it being just a thought bubble (given +2 decades in research that has gone before us) BUT still not at the stage that the FDA will likely just give us a easy pathway for this designation. All IMO and any positive from FDA here will be blue sky.

Nevertheless I contend it won't really matter to us as shareholders given the likely take-up rate and how it will be used as a standard of care once approved. All our target markets have their own National OA Strategies that priorities prevention via weight loss and exercise. The has proven time and time again to be an abject failure due to pain and non-conformity with ad hoc medical plans and follow-ups. Everyone involved from GPs, allied health care workers, orthopaedics, private health care insurers and regulators themselves know this has to change given its critical impact OA has on the majority of people +60 years of age on any given population.